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Discussion 
 
This SELEX experiment, for the selection of HER2 targeting aptamers, resulted in 26 selected RNA aptamers for further individual evaluation. Up till now, we 
were able to identify two aptamers that show binding to HER2 overexpressing SK-OV-3 cancer cells. In addition, we were able to generate silenced SK-OV-3 
cells with minimal remaining HER2 levels, which will be used to obtain more information regarding the binding specificity of the selected aptamers 
Future 
 
Based on several binding properties (affinity, specificity, kinetics), internalization potential, and primary and secondary structures, we will select a small set of 
aptamers which will be conjugated to a chelator and radiolabelled with lutetium-177. These potential therapeutic aptamer-based radiopharmaceuticals will be 
further evaluated in vitro and in vivo.  
SCK•CEN Academy    II    Boeretang 200    II    BE-2400 Mol    II    http://academy.sckcen.be    II    academy@sckcen.be     II   Posternr: 
Development of aptamer-based radiopharmaceuticals  
for targeted cancer imaging and therapy  
 M. Gijs1,2, A. Aerts1, N. Impens1, S. Baatout1, A. Luxen2 
1 Radiobiology Unit, Belgian Nuclear Research Centre, SCK•CEN, Mol, Belgium 




Aptamers are small (5-15 kDa, 15–60 mer), non-coding, single-stranded nucleic acids (DNA or RNA) that can fold 
into unique three-dimensional structures which allow the interaction with a target with high affinity and specificity. 
Aptamers exhibit significant advantages relative to protein therapeutics in terms of size, synthesis, modifications, 
possible targets and immunogenicity. Therefore, aptamers are regarded as promising vector molecules for the 
development of radiopharmaceuticals for molecular cancer imaging or targeted cancer therapy.    
The Human Epidermal growth factor Receptor 2 (HER2) is a transmembrane receptor tyrosine kinase and a member of the HER family. Overexpression of HER2 
is observed in 20 to 30% of breast cancers. Since its role in cancer development and progression, HER2 is attractive for targeted imaging and therapies. 
In this study, we aim to select aptamers targeting HER2 by the use of an in vitro selection process called SELEX (Systematic Evolution of Ligands by EXponential 
enrichment) in collaboration with the Astbury Centre for Structural Molecular Biology of the University of Leeds (United Kingdom). The resulting aptamers are 
evaluated for their binding properties, i.e. affinity and specificity, to their target on cancer cells. In regard to the specificity, a HER2 negative cancer cell line was 
created by removing specific HER2 expression through gene silencing.  
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The unselected library serves as a negative 
control for non-specific binding. We observed a 
dose-dependent fluorescent signal for two 
tested aptamers, B19 and B20, compared to no 
signal for the unselected library which suggests 




Both levels (mRNA and protein) were compared 
to cells which were not transfected (represented 
as 0 hours after transfection). We observed a 
knock-down of 96 % of the mRNA level and 
82.5 % of the protein level at 72 hrs and 96 hrs 
after transfection, respectively. 
 
 
After 15 rounds of selection, the resulted 
aptamer pool was cloned in E. coli. Colony PCR 
revealed 26 selected RNA aptamers with the 
correct insert length (i.e. 121 bp). These 
aptamers will be evaluated further in vitro.  
 
The SELEX process 
 
A pool of 1014 different aptamer candidates (the 
library), containing a 50-mer randomised region 
flanked by two fixed primer ends, was subjected 
to iterative rounds of selection, separation and 
amplification to find candidates with the best 
binding properties. As a target, both the 
purified HER2 protein and HER2 overexpressing 
breast cancer cells (SK-BR-3 cells) were used. In 
order to avoid non-specific binding, extra steps 
using the purified HER3 protein and HER2 low 
expressing breast cancer cells were included. 
 
Evaluation of binding of selected aptamers 
 
Binding of the individual selected RNA aptamers 
was tested on SK-OV-3 cells, a human ovarian 
cancer cell line with overexpression of HER2 by 
flow cytometry. To this end, the aptamers are 
fluorescently labelled via T7 in vitro transcription 
using fluorescein-12-UTP (Roche Applied 
Science).  
 
Generation of a HER2 negative  
cancer cell line through gene silencing 
 
50 nM small interfering RNA (siRNA) targeting 
HER2 mRNA (Dharmacon) was introduced into 
SK-OV-3 cells through lipid-based transfection 
using Lipofectamine RNAiMAX (Invitrogen). The 
HER2 mRNA level was measured by Q-PCR and 




























































Protein level by flow cytometry
SKOV3 cells (blanco)
SKOV3 cells (24 hrs p.t.)
SKOV3 cells (48 hrs p.t.)
SKOV3 cells (72 hrs p.t.)
SKOV3 cells (96 hrs p.t.)






















mRNA level by Q-PCR
SKOV3 cells (blanco)
SKOV3 cells (24 hrs p.t.)
SKOV3 cells (48 hrs p.t.)
SKOV3 cells (72 hrs p.t.)
SKOV3 cells (96 hrs p.t.)
SKOV3 cells (120 hrs p.t.)
MDA-MB-231 cells
MCF7 cells
